Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B.
Authors:
- N C StrynadkaNSN C Strynadka
- R S HodgesRHR S Hodges
- L PereiraLPL Pereira
Open Access
- 1 July 1990
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 86 (1) , 273-278
Abstract
The role of antibody in neonatal herpes simplex virus (HSV) infection remains controversial. A battery of well-characterized monoclonal antibodies to HSV glycoprotein B (gB), and polyclonal antibodies against synthetic peptides of predicted epitopes of HSV glycoprotein D (gD) were used to determine in vitro functional activity and association with protection against lethal infection in a murine model of neonatal HSV disease. Antiviral neutralization activity of HSV was not associated with antibody-dependent cellular cytotoxicity (ADCC) activity to HSV-infected cells in vitro. In a model of high dose challenge (10(4) PFU), protection was not afforded by any antibody alone, but was by antibody plus human mononuclear cells, and highly associated with ADCC functional activity (P less than 0.001). In a low dose challenge model, neutralizing activity of antibody alone was associated with protection in vivo (P less than 0.001). Of the nine neutralizing epitopes of gD in vitro, eight were predicted surface regions. Four of the five epitopic sites of gD (2-21, 267-276, 288-297, and 303-312) that were determined to be important targets of ADCC and in vivo protection were also predicted to be surface regions. The only exception was the antiserum to region 52-61 which was predicted to be buried and also showed these activities. ADCC as well as neutralizing antibody activity are important in protection against neonatal HSV infection.Keywords
This publication has 48 references indexed in Scilit:
- Protection against murine neonatal herpes simplex virus infection by lymphokine-treated human leukocytes.The Journal of Immunology, 1990
- The genetic deficiency of leukocyte surface glycoprotein Mac-1, LFA-1, p150,95 in humans is associated with defective antibody-dependent cellular cytotoxicity in vitro and defective protection against herpes simplex virus infection in vivo.The Journal of Immunology, 1986
- Human T-lymphocyte response in vitro to synthetic peptides of herpes simplex virus glycoprotein D.Proceedings of the National Academy of Sciences, 1985
- Passive Immunization of Mice with Monoclonal Antibodies to Glycoprotein gB of Herpes Simplex VirusMicrobiology and Immunology, 1985
- Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies.Proceedings of the National Academy of Sciences, 1985
- Ontogeny of Protection of Neonatal Mice from Lethal Herpes Simplex Virus Infection by Human Leukocytes, Antiviral Antibody, and Recombinant α-InterferonPediatric Research, 1984
- Analysis in Human Neonates of Defective Antibody-Dependent Cellular Cytotoxicity and Natural Killer Cytotoxicity to Herpes Simplex Virus-Infected CellsThe Journal of Infectious Diseases, 1984
- Identification of Infected Cell-specific Monoclonal Antibodies and their Role in Host Resistance to Ocular Herpes Simplex Virus Type 1 InfectionJournal of General Virology, 1984
- The Relative Role of Transplacental and Milk Immune Transfer in Protection Against Lethal Neonatal Herpes Simplex Virus Infection in MiceThe Journal of Infectious Diseases, 1984
- Neonatal Herpes Simplex Virus Infection: Follow-up Evaluation of Vidarabine TherapyPediatrics, 1983